Transcenta Completes $100 Million Series B+ Financing with China Renaissance as Exclusive Financial Advisor

VCBeat has learned that on January 8, Transcenta Holding, an international biopharmaceutical company with integrated capabilities spanning drug discovery, process development, clinical development, and manufacturing, announced the successful completion of its $100 million Series B+ financing round. The round was co-led by China Resources Zhengda Life Science Fund and Fortune Capital. New investors participating in the follow-on investment included Yipu Capital, China Merchants Capital’s Guodiao M&A Fund, and China Equity Group. Existing investors, including Lilly Asia Ventures, Temasek, Hillhouse Capital, Teyue Fund, Sequoia Capital China, and ARCH Venture Partners, continued their participation. China Renaissance served as the exclusive financial advisor for this transaction.

Since its merger and establishment in early 2019, Transcenta Holding has built an outstanding team with extensive international experience. The company has expanded its R&D pipeline to include more than 10 novel drug candidates spanning oncology, bone diseases, nephrology, and other therapeutic areas, and has adopted continuous perfusion production technology at its process development and manufacturing center in Hangzhou. Meanwhile, Transcenta Holding successfully entered into an exclusive in-licensing agreement with Eli Lilly and Company, securing the rights for the Greater China region to Lilly’s entire innovative biopharmaceutical portfolio for bone diseases, including Blosozumab, which has completed Phase II clinical trials.

Dr. Qian Xueming, Co-founder and CEO of Transcenta Holding, stated, “We are deeply grateful for the continued support from our existing investors and the trust placed in us by new investors. The proceeds from this financing will be used to advance key projects in our pipeline, including second-generation anti-Claudin 18.2 antibodies, PDL1-TGFβ bispecific antibodies, multiple undisclosed tumor-targeting drug candidates, and Blosozumab, a revolutionary therapy for osteoporosis. Meanwhile, Transcenta Holding will further strengthen its continuous manufacturing capabilities, expressing strong confidence that the comprehensive application of this technology will significantly reduce production costs. Finally, the company will further enhance the strength of its core team to prepare for an initial public offering (IPO).”

Dr. Zhao Yining, Co-founder and Executive Chairman of Transcenta Holding, stated, “This marks the first successful financing round for Transcenta following its merger, and we extend our sincere gratitude to all new investors for their trust in us. We will concentrate our resources to fully accelerate the development of our pipeline products. Transcenta has evolved into a fully integrated biopharmaceutical company. Committed to excellence, we strive to deliver high-quality, affordable biologics to more patients at the earliest possible time.”

Mr. Liu Da, Managing Director of the China Resources Zhengda Life Science Fund, stated, “We are delighted to join other renowned investors in participating in this financing round of Transcenta Holding, collectively supporting the elite team led by two outstanding executives, Dr. Qian Xueming and Dr. Zhao Yining. Transcenta Holding boasts cutting-edge technology platforms and has successfully integrated the entire process from drug discovery to manufacturing. Sharing a common vision with Transcenta Holding, we aim to provide affordable innovative biologics to patients worldwide. Furthermore, we will actively leverage the resources of China Resources Group and CP Group to support Transcenta Holding’s development. I am confident that Transcenta Holding will become a unicorn company.”

Mr. Qi Shen, Senior Vice President of Fortune Capital and Managing Partner for Healthcare, stated, “We are delighted to join both new and existing investors in supporting the outstanding work of the two founders and their team. Transcenta Holding has a rich pipeline across multiple key therapeutic areas, combining innovation, stability, and significant growth potential. Leveraging its rare, integrated end-to-end drug R&D and manufacturing technology platform, we are confident that Transcenta Holding will firmly maintain control over its four core competitive advantages—innovation, speed, quality, and cost—and is poised to become one of the most sustainably competitive players in China’s biopharmaceutical R&D sector.”

Mr. Xie Yijing, Managing Director and Head of the Healthcare and Life Sciences Group at China Renaissance Capital, stated, “We are honored to have assisted Transcenta Holding in successfully completing its first round of financing following the merger. We believe that, leveraging its unique integrated technology platform and top-tier management capabilities, Transcenta Holding will emerge as a leader in the biopharmaceutical sector.”

Transcenta Holding is a clinical-stage biopharmaceutical company with fully integrated capabilities in biomedical research, development, and manufacturing. The company has successfully established a global business footprint: it operates drug discovery, clinical, and translational research centers in Suzhou; process and product development centers and drug manufacturing bases in Hangzhou; clinical development centers in Shanghai, Guangzhou, Beijing, and Princeton, USA; and an external collaboration center in Boston, USA. Transcenta’s development pipeline comprises more than ten novel drug molecules across oncology and selected non-oncology therapeutic areas. To date, the company has raised over USD 230 million in total financing.